American Society of Hematology

Fig. 1.

$Fig. 1. β-Catenin protein levels in normal peripheral blood T cells, leukemia/lymphoma cell lines, and primary leukemia cells. / (A) Peripheral blood obtained from healthy volunteers was separated on Ficoll gradients, and the mononuclear cells were depleted of monocytes by brief incubation on plastic. T cells were enriched by removal of natural killer cells and B cells using Dynal beads coated with anti-CD16 and anti-CD19 antibodies, respectively. β-Catenin and actin protein levels in the resulting populations were measured by Western blot analysis. (B) β-Catenin and actin in total cell lysates from leukemia/lymphoma cell lines were determined by Western blot analysis with chemiluminescence detection. (C) β-Catenin and actin in total cell lysates from primary leukemia cells were determined. (Lane 1, AML-M4, newly diagnosed; lane 2, AML-M2, newly diagnosed; lane 3, AML-M5, newly diagnosed; lane 4, AML-M4, refractory; lane 5, AML-M5, refractory; lane 6, AML-M5, newly diagnosed; lane 7, AML-M0, newly diagnosed; lane 8, AML-M3, newly diagnosed; lane 9, CML blast crisis; lane 10, CML, chronic phase; lane 11, relapsed T-ALL).$

β-Catenin protein levels in normal peripheral blood T cells, leukemia/lymphoma cell lines, and primary leukemia cells.

(A) Peripheral blood obtained from healthy volunteers was separated on Ficoll gradients, and the mononuclear cells were depleted of monocytes by brief incubation on plastic. T cells were enriched by removal of natural killer cells and B cells using Dynal beads coated with anti-CD16 and anti-CD19 antibodies, respectively. β-Catenin and actin protein levels in the resulting populations were measured by Western blot analysis. (B) β-Catenin and actin in total cell lysates from leukemia/lymphoma cell lines were determined by Western blot analysis with chemiluminescence detection. (C) β-Catenin and actin in total cell lysates from primary leukemia cells were determined. (Lane 1, AML-M4, newly diagnosed; lane 2, AML-M2, newly diagnosed; lane 3, AML-M5, newly diagnosed; lane 4, AML-M4, refractory; lane 5, AML-M5, refractory; lane 6, AML-M5, newly diagnosed; lane 7, AML-M0, newly diagnosed; lane 8, AML-M3, newly diagnosed; lane 9, CML blast crisis; lane 10, CML, chronic phase; lane 11, relapsed T-ALL).

This Feature Is Available To Subscribers Only